glaxosmithkline intellectual property limited
glaxosmithkline intellectual property limited Company Information
Company Number
08283186
Website
http://gsk.comRegistered Address
gsk medicines research centre, gunnels wood road, stevenage, SG1 2NY
Industry
Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
Telephone
02080475000
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
glaxo group ltd 100%
glaxosmithkline intellectual property limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED at £9b based on a Turnover of £2.1b and 4.3x industry multiple (adjusted for size and gross margin).
glaxosmithkline intellectual property limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED at £20.8b based on an EBITDA of £1.3b and a 16.31x industry multiple (adjusted for size and gross margin).
glaxosmithkline intellectual property limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED at £16.1b based on Net Assets of £9.4b and 1.71x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Intellectual Property Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Glaxosmithkline Intellectual Property Limited Overview
Glaxosmithkline Intellectual Property Limited is a live company located in stevenage, SG1 2NY with a Companies House number of 08283186. It operates in the activities of other holding companies n.e.c. sector, SIC Code 64209. Founded in November 2012, it's largest shareholder is glaxo group ltd with a 100% stake. Glaxosmithkline Intellectual Property Limited is a established, mega sized company, Pomanda has estimated its turnover at £2.1b with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Glaxosmithkline Intellectual Property Limited Health Check
Pomanda's financial health check has awarded Glaxosmithkline Intellectual Property Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 1 areas for improvement. Company Health Check FAQs
5 Strong
1 Regular
1 Weak
Size
annual sales of £2.1b, make it larger than the average company (£18.1m)
£2.1b - Glaxosmithkline Intellectual Property Limited
£18.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 2%, show it is growing at a slower rate (6.7%)
2% - Glaxosmithkline Intellectual Property Limited
6.7% - Industry AVG
Production
with a gross margin of 69.5%, this company has a lower cost of product (36.1%)
69.5% - Glaxosmithkline Intellectual Property Limited
36.1% - Industry AVG
Profitability
an operating margin of 47% make it more profitable than the average company (5.1%)
47% - Glaxosmithkline Intellectual Property Limited
5.1% - Industry AVG
Employees
with 11749 employees, this is above the industry average (106)
- Glaxosmithkline Intellectual Property Limited
106 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Intellectual Property Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £178.7k, this is equally as efficient (£178.7k)
- Glaxosmithkline Intellectual Property Limited
£178.7k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Intellectual Property Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 4.6%, this is a lower level of debt than the average (69.9%)
4.6% - Glaxosmithkline Intellectual Property Limited
69.9% - Industry AVG
glaxosmithkline intellectual property limited Credit Report and Business Information
Glaxosmithkline Intellectual Property Limited Competitor Analysis
Perform a competitor analysis for glaxosmithkline intellectual property limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
glaxosmithkline intellectual property limited Ownership
GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED group structure
Glaxosmithkline Intellectual Property Limited has no subsidiary companies.
Ultimate parent company
2 parents
GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED
08283186
glaxosmithkline intellectual property limited directors
Glaxosmithkline Intellectual Property Limited currently has 6 directors. The longest serving directors include Mr Adam Walker (Mar 2013) and Mr James Wheatcroft (Jul 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Adam Walker | United Kingdom | 56 years | Mar 2013 | - | Director |
| Mr James Wheatcroft | 56 years | Jul 2019 | - | Director | |
| Ms Jill Anderson | United Kingdom | 60 years | Mar 2023 | - | Director |
| Mr Graham Rivers | United Kingdom | 53 years | Jul 2023 | - | Director |
| Mr Gregory Reinaud | England | 47 years | Jan 2024 | - | Director |
| Mrs Jemma-Louise Reynolds | United Kingdom | 34 years | Apr 2024 | - | Director |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED financials
Glaxosmithkline Intellectual Property Limited's latest turnover from December 2022 is £2.1 billion and the company has net assets of £9.4 billion. According to their latest financial statements, we estimate that Glaxosmithkline Intellectual Property Limited has 11,749 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 2,099,159,000 | 1,976,546,000 | 1,871,158,000 | 1,998,603,000 | 2,107,423,000 | 3,218,821,000 | 3,430,942,000 | 2,976,490,000 | 3,517,577,000 | 1,394,125,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 639,402,000 | 659,567,000 | 705,343,000 | 910,206,000 | 980,393,000 | 1,205,559,000 | 1,405,186,000 | 1,329,332,000 | 1,509,305,000 | 251,464,000 |
| Gross Profit | 1,459,757,000 | 1,316,979,000 | 1,165,815,000 | 1,088,397,000 | 1,127,030,000 | 2,013,262,000 | 2,025,756,000 | 1,647,158,000 | 2,008,272,000 | 1,142,661,000 |
| Admin Expenses | 473,822,000 | 463,270,000 | 420,332,000 | 519,561,000 | 492,401,000 | 557,667,000 | 703,767,000 | 631,995,000 | 1,081,367,000 | 929,325,000 |
| Operating Profit | 985,935,000 | 853,709,000 | 745,483,000 | 568,836,000 | 634,629,000 | 1,455,595,000 | 1,321,989,000 | 1,015,163,000 | 926,905,000 | 213,336,000 |
| Interest Payable | 0 | 0 | 90,000 | 273,000 | 0 | 0 | 0 | 823,000 | 4,031,000 | 457,000 |
| Interest Receivable | 111,391,000 | 154,000 | 6,682,000 | 26,284,000 | 17,222,000 | 3,922,000 | 2,062,000 | 0 | 0 | 0 |
| Pre-Tax Profit | 1,097,326,000 | 853,863,000 | 752,075,000 | 594,847,000 | 651,851,000 | 1,459,517,000 | 1,324,051,000 | 1,014,340,000 | 922,874,000 | 212,879,000 |
| Tax | -207,974,000 | -107,468,000 | -107,290,000 | -81,546,000 | -20,449,000 | -177,202,000 | -179,360,000 | -183,650,000 | -138,975,000 | -71,283,000 |
| Profit After Tax | 889,352,000 | 746,395,000 | 644,785,000 | 513,301,000 | 631,402,000 | 1,282,315,000 | 1,144,691,000 | 830,690,000 | 783,899,000 | 141,596,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15,851,000 | 0 |
| Retained Profit | 889,352,000 | 746,395,000 | 644,785,000 | 513,301,000 | 631,402,000 | 1,282,315,000 | 1,144,691,000 | 830,690,000 | 768,048,000 | 141,596,000 |
| Employee Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Number Of Employees | ||||||||||
| EBITDA* | 1,278,195,000 | 1,158,564,000 | 1,056,071,000 | 886,493,000 | 933,217,000 | 1,782,234,000 | 1,404,864,000 | 1,349,034,000 | 1,289,346,000 | 495,887,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 652,085,000 | 938,493,000 | 1,234,896,000 | 1,531,261,000 | 1,827,018,000 | 2,117,904,000 | 2,413,515,000 | 2,803,567,000 | 3,120,334,000 | 2,906,455,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 8,995,837,000 | 7,626,000 | 9,563,000 | 0 | 0 | 0 | 0 | 0 | 0 | 5,172,000 |
| Total Fixed Assets | 9,647,922,000 | 946,119,000 | 1,244,459,000 | 1,531,261,000 | 1,827,018,000 | 2,117,904,000 | 2,413,515,000 | 2,803,567,000 | 3,120,334,000 | 2,911,627,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 62,022,000 | 7,705,419,000 | 6,585,076,000 | 6,004,691,000 | 4,941,091,000 | 4,443,961,000 | 2,781,149,000 | 1,444,285,000 | 1,048,935,000 | 1,187,692,000 |
| Misc Debtors | 174,502,000 | 118,868,000 | 101,638,000 | 95,325,000 | 97,061,000 | 70,015,000 | 71,867,000 | 47,242,000 | 60,893,000 | 62,751,000 |
| Cash | 0 | 0 | 0 | 0 | 3,000 | 33,000 | 28,000 | 37,000 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41,466,000 | 0 |
| total current assets | 236,524,000 | 7,824,287,000 | 6,686,714,000 | 6,100,016,000 | 5,038,155,000 | 4,514,009,000 | 2,853,044,000 | 1,491,564,000 | 1,151,294,000 | 1,250,443,000 |
| total assets | 9,884,446,000 | 8,770,406,000 | 7,931,173,000 | 7,631,277,000 | 6,865,173,000 | 6,631,913,000 | 5,266,559,000 | 4,295,131,000 | 4,271,628,000 | 4,162,070,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 556,000 | 528,000 | 1,998,000 | 0 | 0 | 1,521,070,000 | 1,448,000 |
| Group/Directors Accounts | 184,435,000 | 76,910,000 | 7,593,000 | 374,697,000 | 140,089,000 | 366,605,000 | 261,384,000 | 455,991,000 | 0 | 2,018,919,000 |
| other short term finances | 0 | 0 | 300,000 | 216,000 | 46,000 | 99,000 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 248,909,000 | 151,394,000 | 104,206,000 | 76,015,000 | 70,174,000 | 244,323,000 | 265,985,000 | 250,171,000 | 0 | 170,650,000 |
| total current liabilities | 433,344,000 | 228,304,000 | 112,099,000 | 451,484,000 | 210,837,000 | 613,025,000 | 527,369,000 | 706,162,000 | 1,521,070,000 | 2,191,017,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 23,421,000 | 3,773,000 | 27,140,000 | 32,644,000 | 20,488,000 | 16,442,000 | 19,059,000 | 13,529,000 | 5,808,000 | 17,505,000 |
| total long term liabilities | 23,421,000 | 3,773,000 | 27,140,000 | 32,644,000 | 20,488,000 | 16,442,000 | 19,059,000 | 13,529,000 | 5,808,000 | 17,505,000 |
| total liabilities | 456,765,000 | 232,077,000 | 139,239,000 | 484,128,000 | 231,325,000 | 629,467,000 | 546,428,000 | 719,691,000 | 1,526,878,000 | 2,208,522,000 |
| net assets | 9,427,681,000 | 8,538,329,000 | 7,791,934,000 | 7,147,149,000 | 6,633,848,000 | 6,002,446,000 | 4,720,131,000 | 3,575,440,000 | 2,744,750,000 | 1,953,548,000 |
| total shareholders funds | 9,427,681,000 | 8,538,329,000 | 7,791,934,000 | 7,147,149,000 | 6,633,848,000 | 6,002,446,000 | 4,720,131,000 | 3,575,440,000 | 2,744,750,000 | 1,953,548,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Profit | 985,935,000 | 853,709,000 | 745,483,000 | 568,836,000 | 634,629,000 | 1,455,595,000 | 1,321,989,000 | 1,015,163,000 | 926,905,000 | 213,336,000 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 292,260,000 | 304,855,000 | 310,588,000 | 317,657,000 | 298,588,000 | 326,639,000 | 82,875,000 | 333,871,000 | 362,441,000 | 282,551,000 |
| Tax | -207,974,000 | -107,468,000 | -107,290,000 | -81,546,000 | -20,449,000 | -177,202,000 | -179,360,000 | -183,650,000 | -138,975,000 | -71,283,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 1,400,448,000 | 1,135,636,000 | 596,261,000 | 1,061,864,000 | 524,176,000 | 1,660,960,000 | 1,361,489,000 | 381,699,000 | -145,787,000 | 1,255,615,000 |
| Creditors | 0 | 0 | -556,000 | 28,000 | -1,470,000 | 1,998,000 | 0 | -1,521,070,000 | 1,519,622,000 | 1,448,000 |
| Accruals and Deferred Income | 97,515,000 | 47,188,000 | 28,191,000 | 5,841,000 | -174,149,000 | -21,662,000 | 15,814,000 | 250,171,000 | -170,650,000 | 170,650,000 |
| Deferred Taxes & Provisions | 19,648,000 | -23,367,000 | -5,504,000 | 12,156,000 | 4,046,000 | -2,617,000 | 5,530,000 | 7,721,000 | -11,697,000 | 17,505,000 |
| Cash flow from operations | -213,064,000 | -60,719,000 | 374,651,000 | -238,892,000 | 217,019,000 | -78,209,000 | -114,641,000 | -479,493,000 | 2,633,433,000 | -641,408,000 |
| Investing Activities | ||||||||||
| capital expenditure | ||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||
| Financing Activities | ||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 107,525,000 | 69,317,000 | -367,104,000 | 234,608,000 | -226,516,000 | 105,221,000 | -194,607,000 | 455,991,000 | -2,018,919,000 | 2,018,919,000 |
| Other Short Term Loans | 0 | -300,000 | 84,000 | 170,000 | -53,000 | 99,000 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||
| interest | 111,391,000 | 154,000 | 6,592,000 | 26,011,000 | 17,222,000 | 3,922,000 | 2,062,000 | -823,000 | -4,031,000 | -457,000 |
| cash flow from financing | 218,916,000 | 69,171,000 | -360,428,000 | 260,789,000 | -209,347,000 | 109,242,000 | -192,545,000 | 455,168,000 | -1,999,796,000 | 3,830,414,000 |
| cash and cash equivalents | ||||||||||
| cash | 0 | 0 | 0 | -3,000 | -30,000 | 5,000 | -9,000 | 37,000 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | -3,000 | -30,000 | 5,000 | -9,000 | 37,000 | 0 | 0 |
P&L
December 2022turnover
2.1b
+6%
operating profit
985.9m
+15%
gross margin
69.6%
+4.37%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
9.4b
+0.1%
total assets
9.9b
+0.13%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
glaxosmithkline intellectual property limited company details
company number
08283186
Type
Private limited with Share Capital
industry
64209 - Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
incorporation date
November 2012
age
12
accounts
Full Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
gsk medicines research centre, gunnels wood road, stevenage, SG1 2NY
last accounts submitted
December 2022
glaxosmithkline intellectual property limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to glaxosmithkline intellectual property limited.
glaxosmithkline intellectual property limited Companies House Filings - See Documents
| date | description | view/download |
|---|
